Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis

Area of Science:

• Cardiovascular Biology
• Vascular Physiology
• Lipid Metabolism

Background:

• Atherosclerosis is associated with altered vascular prostacyclin (PGI2) production.
• Previous hypotheses suggested reduced PGI2 in atherosclerotic arteries, potentially leading to vasospasm and thrombosis.

Purpose of the Study:

• To re-examine the concept of PGI2 production in atherosclerosis.
• To compare PGI2 and thromboxane A2 (TXA2) biosynthesis in atherosclerotic versus non-atherosclerotic rabbit aortas.

Main Methods:

• Measurement of spontaneous and arachidonate-induced PGI2 and TXA2 biosynthesis using radioimmunoassay (RIA) in rabbit aortic segments.
• Inhibition studies with indomethacin and a selective TXA2 inhibitor (OKY-046) to confirm eicosanoid identity.
• Experiments using [14C]arachidonate to assess arachidonate release and metabolism.

Main Results:

• PGI2 and TXA2 formation were significantly increased in atherosclerotic aortic segments compared to non-atherosclerotic segments.
• Increased arachidonate release was observed in atherosclerotic arteries, correlating with higher eicosanoid synthesis.
• Inhibition studies confirmed the identity of PGI2 and TXA2 metabolites.

Conclusions:

• Arterial synthesis of both PGI2 and TXA2 is elevated in atherosclerosis.
• This increased eicosanoid production is linked to enhanced arachidonate release from arterial tissue.
• The study challenges the notion of reduced PGI2 in atherosclerosis, suggesting a more complex role in the disease process.